Shepherd FA - Search Results

1

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

Kuang S, Fung AS, Perdrizet KA, Chen K, Li JJN, Le LW, Cabanero M, Karsaneh OAA, Tsao MS, Morganstein J, Ranich L, Smith AC, Wei C, Cheung C, Shepherd FA, Liu G, Bradbury P, Pal P, Schwock J, Sacher AG, Law JH, Stockley TL, Leighl NB. Kuang S, et al. Among authors: shepherd fa. Curr Oncol. 2022 Jun 22;29(7):4428-4437. doi: 10.3390/curroncol29070352. Curr Oncol. 2022. PMID: 35877212 Free PMC article.

2

Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.

Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Leighl NB, et al. Among authors: shepherd fa. J Clin Oncol. 2002 Mar 1;20(5):1344-52. doi: 10.1200/JCO.2002.20.5.1344. J Clin Oncol. 2002. PMID: 11870178

3

Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.

Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS. Wigle DA, et al. Among authors: shepherd fa. Cancer Res. 2002 Jun 1;62(11):3005-8. Cancer Res. 2002. PMID: 12036904

4

Pemetrexed in the treatment of non-small cell lung cancer.

Shepherd FA. Shepherd FA. Semin Oncol. 2002 Dec;29(6 Suppl 18):43-8. doi: 10.1053/sonc.2002.37470. Semin Oncol. 2002. PMID: 12571810 Review.

5

Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA. Blackhall FH, et al. Among authors: shepherd fa. Clin Cancer Res. 2003 Jun;9(6):2241-7. Clin Cancer Res. 2003. PMID: 12796392

6

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

Sridhar SS, Seymour L, Shepherd FA. Sridhar SS, et al. Among authors: shepherd fa. Lancet Oncol. 2003 Jul;4(7):397-406. doi: 10.1016/s1470-2045(03)01137-9. Lancet Oncol. 2003. PMID: 12850190 Review.

7

Second-line chemotherapy for non-small cell lung cancer.

Shepherd FA. Shepherd FA. Expert Rev Anticancer Ther. 2003 Aug;3(4):435-42. doi: 10.1586/14737140.3.4.435. Expert Rev Anticancer Ther. 2003. PMID: 12934656 Review.

8

A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.

Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP, David Walde PL, Rudinskas LC, Rahim YH, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Among authors: shepherd fa. Clin Lung Cancer. 2003 Sep;5(2):107-12. doi: 10.3816/CLC.2003.n.024. Clin Lung Cancer. 2003. PMID: 14596693 Clinical Trial.

9

Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker.

Zhu CQ, Blackhall FH, Pintilie M, Iyengar P, Liu N, Ho J, Chomiak T, Lau D, Winton T, Shepherd FA, Tsao MS. Zhu CQ, et al. Among authors: shepherd fa. Clin Cancer Res. 2004 Mar 15;10(6):1984-91. doi: 10.1158/1078-0432.ccr-03-0470. Clin Cancer Res. 2004. PMID: 15041716

10

Current paradigms in first-line treatment of non-small-cell lung cancer.

Shepherd FA. Shepherd FA. Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):13-20. Oncology (Williston Park). 2004. PMID: 15339054 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

548 results

Search Page